Vaxart, Inc. (VXRT)
Vaxart, Inc. (VXRT)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | NaN | 104,239 | NaN | NaN |
| Research and development expense-Norovirus Program | NaN | 411 | NaN | NaN |
| Research and development expense-Covid19Program | NaN | 36,636 | NaN | NaN |
| Research and development expense-Other Programs | NaN | -1 | NaN | NaN |
| Research and development expense-Preclinical Research | NaN | 45 | NaN | NaN |
| Research and development expense-Process Development Program | NaN | 0 | NaN | NaN |
| Research and development expense-Internal Research And Development Costs | NaN | 8,059 | NaN | NaN |
| General and administrative | NaN | 3,666 | NaN | NaN |
| Interest income | NaN | 547 | NaN | NaN |
| Non-cash interest expense related to sale of future royalties | NaN | 546 | NaN | NaN |
| Other segment items | NaN | 35 | NaN | NaN |
| Income tax expense (benefit) | NaN | 344 | NaN | NaN |
| Net income (loss) | 5,179 | 55,045 | -8,141 | -30,577 |
| Depreciation and amortization | 1,126 | 2,055 | 2,080 | 4,444 |
| Loss on sale of property and equipment | -10 | -33 | -5 | NaN |
| Net accretion of discounts on investments | 56 | 71 | 42 | 165 |
| Gain on modification of lease liability | NaN | 1,005 | NaN | NaN |
| Stock-based compensation | 1,482 | 1,716 | 2,018 | 4,580 |
| Non-cash interest expense related to sale of future royalties | 505 | 546 | 607 | 1,670 |
| Other accrued liabilities | NaN | NaN | 8,513 | 22,959 |
| Non-cash revenue related to sale of future royalties | 331 | 0 | 0 | 4,521 |
| Accounts receivable | -7,425 | -28,152 | 38,435 | -1,480 |
| Unbilled receivable from government contracts | 13,654 | -6,448 | 6,448 | 30,573 |
| Prepaid expenses and other assets | -7,889 | 18,054 | -417 | -1,534 |
| Prepaid clinical services, long-term | NaN | -34,898 | 0 | NaN |
| Accounts payable | 2,674 | -31,579 | 42,570 | 3,648 |
| Deferred revenue-Government Contract | -45 | -64,760 | -549 | -23 |
| Deferred revenue-Collaboration Revenue | -2,815 | 14,976 | NaN | NaN |
| Accrued and other liabilities | -11,443 | 33,735 | NaN | NaN |
| Net cash used in operating activities | -2,054 | 30,663 | 2,595 | -25,544 |
| Purchases of property and equipment | 448 | 1 | 117 | 27 |
| Proceeds from sale of property and equipment | 3 | 0 | 5 | NaN |
| Purchases of investments | 10,231 | 4,010 | 9,410 | 9,808 |
| Proceeds from maturities of investments | 10,000 | 6,000 | 3,700 | 30,300 |
| Net cash (used in) provided by investing activities | -676 | 1,989 | -5,822 | 20,465 |
| Net proceeds from issuance of common stock-Ra Capital Healthcare Fund2025 | NaN | 4,201 | NaN | NaN |
| Net proceeds from issuance of common stock-June2024Offering | NaN | 0 | 0 | 0 |
| Proceeds from issuance of treasury stock under the employee stock purchase plan | NaN | 102 | 0 | 79 |
| Net proceeds from issuance of common stock-Atthemarket Facility | NaN | 0 | 0 | 53 |
| Proceeds from issuance of common stock under the employee stock purchase plan | NaN | 0 | 0 | 0 |
| Net proceeds from issuance of common stock-RACapital Healthcare Fund2024 | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock upon exercise of stock options | 0 | 0 | 0 | 3 |
| Shares acquired to settle employee tax withholding liabilities | 338 | 21 | 4 | 174 |
| Net cash used in financing activities | -338 | 4,282 | -4 | -39 |
| Net increase (decrease) in cash and cash equivalents | -3,068 | 36,934 | -3,231 | -5,118 |
| Cash and cash equivalents at beginning of the period | 53,814 | 16,880 | 25,229 | NaN |
| Cash and cash equivalents at end of the period | 50,746 | 53,814 | 16,880 | NaN |